Roche, Fujirebio partner for new ovarian cancer test

MALVERN, Pa. Roche Diagnostics and Fujirebio have entered a license and supply agreement for a new test for ovarian cancer, the two companies announced on Tuesday, Dec. 16.

Under the agreement, Roche will develop an assay kit using Fujirebio's HE4 test on its automated immunoassay analyzers.

Fujirebio developed the HE4 test for use in conjunction with its CA125 biomarker. The company said that the combination provides clinicians with a diagnostic tool more sensitive and specific than CA125 alone.

"This novel biomarker HE4 will allow our longstanding partner, Roche Diagnostics, to provide clinicians worldwide with a much-needed tool to better define a pelvic mass, enabling women at higher risk for cancer to see the right physician earlier," Fujirebio president and CEO Paul Touhey said in a statement.